Market revenue in 2023 | USD 162.6 million |
Market revenue in 2030 | USD 514.4 million |
Growth rate | 17.9% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 54.43% in 2023. Horizon Databook has segmented the Australia structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
The Australian structural heart devices market is experiencing a surge, with TAVR procedures leading the charge. This minimally invasive approach is addressing a critical need in Australia, a country with a high prevalence of aortic stenosis, a condition affecting the heart's aortic valve.
Research published in BMC Health in 2021 paints a clear picture: the number of Australians aged 60 and over developing severe aortic stenosis is projected to rise significantly in the coming years. This translates to a growing demand for effective treatment options, and TAVR is stepping up to the challenge.
Moreover, Australia is committed to monitoring and improving TAVR procedures. The Transcatheter Aortic Valve Implantation Registry (TAVI-R), a collaborative effort between SAHMRI and ACOR, plays a key role. This registry meticulously tracks TAVR procedures across the country, providing valuable data on their safety, effectiveness, and potential areas for improvement.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia structural heart devices market , including forecasts for subscribers. This country databook contains high-level insights into Australia structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account